menu search

Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting

HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...

November 1, 2023, 11:30 am

Sensei biotherapeutics appoints stephanie krebs, ms, mba, as chief business officer

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discov...

November 1, 2023, 11:30 am

Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting

– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools –...

November 1, 2023, 10:30 am

Why is mainz biomed (mynz) stock moving today?

Mainz Biomed (NASDAQ: MYNZ ) stock is on the move Wednesday after the molecular genetics cancer diagno...

November 1, 2023, 8:40 am

Affimed to participate in upcoming investor conferences

MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncolog...

November 1, 2023, 6:30 am

Scancell melanoma trial data chosen for poster presentation at sitc

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors that it has been selected for a poster presentation of data from the first stage of its Pha...

November 1, 2023, 4:16 am

Astrazeneca inks gene editing deal that could end up costing it $2.5bn

AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS) ...

November 1, 2023, 3:59 am

Poolbeg investor meeting will take a deep dive into lead programme

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) is hosting an investor and analyst meeting focusing on its POLB 001 Oncology Programme, targeting cytokin...

November 1, 2023, 3:34 am

Bayer ordered to pay $332 mln in roundup cancer trial -law.com

A California jury found Bayer liable in a case brought by a man who claimed his cancer was due to expos...

October 31, 2023, 7:46 pm

Mersana therapeutics to host third quarter 2023 conference call on november 7, 2023

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on d...

October 31, 2023, 4:30 pm

Revolution medicines to report financial results for third quarter 2023 after market close on november 6, 2023

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel ...

October 31, 2023, 4:15 pm

Pfizer to sees no major m&a activity in 2024: ceo bourla

Pfizer Chairman and CEO Albert Bourla says the company is still in the market for acquisitions following its $43 billion acquisition of ...

October 31, 2023, 3:30 pm

Analyzing the acquisition potential of immunogen

ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted ...

October 31, 2023, 3:25 pm

Drugmaker incyte's quarterly profit beats on lower costs

Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood ...

October 31, 2023, 9:48 am

Xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered,

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and devel...

October 31, 2023, 9:15 am

Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, dev...

October 31, 2023, 9:05 am

Perimeter medical imaging ai initiates new clinical trial site at university of washington's fred hutch cancer center

Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) said it has initiated an additional clinical trial site at the Fred Hutch ...

October 31, 2023, 8:08 am

Scancell makes strong progress with lead immunotherapy assets

Key highlights for biotech group Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s financial year ending April 30 included a positive data reading arising...

October 31, 2023, 4:48 am

Transcode therapeutics withdraws public offering

BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more...

October 30, 2023, 8:33 pm

Atossa therapeutics' (z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ

Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being evaluated in a Phase 2 study aimed at preventing ...

October 30, 2023, 3:11 pm


Search within

Pages Search Results: